InDex Pharmaceuticals Holding Past Earnings Performance
Past criteria checks 0/6
InDex Pharmaceuticals Holding has been growing earnings at an average annual rate of 2.7%, while the Pharmaceuticals industry saw earnings growing at 9.7% annually. Revenues have been growing at an average rate of 89.5% per year.
Key information
2.7%
Earnings growth rate
53.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 30.5% |
| Revenue growth rate | 89.5% |
| Return on equity | -23.9% |
| Net Margin | -52.1% |
| Next Earnings Update | 20 Aug 2024 |
Recent past performance updates
Recent updates
Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce
Apr 28
We're Keeping An Eye On InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Rate
Jul 11We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth
Jan 21We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth
Aug 31Here's Why We're Watching InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Situation
Mar 29InDex Pharmaceuticals Holding's (STO:INDEX) Shareholders Are Down 24% On Their Investment Over The Past Year.
Feb 04
How Much Are InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Insiders Spending On Buying Shares?
Dec 21Revenue & Expenses BreakdownBeta
How InDex Pharmaceuticals Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 108 | -56 | 171 | 0 |
| 31 Dec 23 | 98 | -95 | 188 | 0 |
| 30 Sep 23 | 98 | -46 | 143 | 0 |
| 30 Jun 23 | 98 | -12 | 134 | 0 |
| 31 Mar 23 | 1 | -123 | 156 | 0 |
| 31 Dec 22 | 1 | -100 | 140 | 0 |
| 30 Sep 22 | -2 | -67 | 123 | 0 |
| 30 Jun 22 | -2 | -92 | 127 | 0 |
| 31 Mar 22 | 0 | -113 | 117 | 0 |
| 31 Dec 21 | 0 | -103 | 100 | 0 |
| 30 Sep 21 | 3 | -90 | 86 | 0 |
| 30 Jun 21 | 3 | -70 | 59 | 0 |
| 31 Mar 21 | 0 | -43 | 35 | 0 |
| 31 Dec 20 | 0 | -57 | 41 | 0 |
| 30 Sep 20 | 0 | -73 | 53 | 0 |
| 30 Jun 20 | 0 | -92 | 73 | 0 |
| 31 Mar 20 | 0 | -95 | 80 | 0 |
| 31 Dec 19 | 0 | -88 | 83 | 0 |
| 30 Sep 19 | 0 | -84 | 83 | 0 |
| 30 Jun 19 | 0 | -72 | 71 | 0 |
| 31 Mar 19 | 0 | -81 | 80 | 0 |
| 31 Dec 18 | 1 | -82 | 81 | 0 |
| 30 Sep 18 | 0 | -82 | 82 | 0 |
| 30 Jun 18 | 0 | -80 | 80 | 0 |
| 31 Mar 18 | 0 | -69 | 69 | 0 |
| 31 Dec 17 | 0 | -73 | 63 | 0 |
| 30 Sep 17 | 0 | -67 | 54 | 0 |
| 30 Jun 17 | 0 | -61 | 48 | 0 |
| 31 Mar 17 | 0 | -56 | 41 | 0 |
| 31 Dec 16 | 0 | -41 | 34 | 0 |
| 30 Sep 16 | 0 | -31 | 28 | 0 |
| 30 Jun 16 | 0 | -31 | 29 | 0 |
| 31 Mar 16 | 0 | -29 | 28 | 0 |
| 31 Dec 15 | 0 | -30 | 28 | 0 |
| 30 Sep 15 | 0 | -33 | 30 | 0 |
| 30 Jun 15 | 0 | -36 | 32 | 0 |
| 31 Mar 15 | 23 | -25 | 42 | 0 |
| 31 Dec 14 | 45 | -15 | 52 | 0 |
| 31 Dec 13 | 1 | -68 | 62 | 0 |
Quality Earnings: INDEX is currently unprofitable.
Growing Profit Margin: INDEX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: INDEX is unprofitable, but has reduced losses over the past 5 years at a rate of 2.7% per year.
Accelerating Growth: Unable to compare INDEX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INDEX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3%).
Return on Equity
High ROE: INDEX has a negative Return on Equity (-23.93%), as it is currently unprofitable.